Targeted Molecular Therapy
The treatment of advanced thyroid cancer has developed with increased understanding of the molecular basis of the disease. Alongside this targeted therapies have been developed, and there is evidence of efficacy for multikinase inhibitors in improving progression-free survival in this population of patients. An impact on overall survival, however, has yet to be proven. The design and results of the four published phase III randomised controlled trials leading to the licensing of vandetanib, cabozantinib, sorafenib and lenvatinib in advanced thyroid cancer are discussed. Identification of predictive biomarkers including histopathological, molecular and demographic factors may guide the most effective treatment selection for individual patients in the future and remains an area of active research. Continued enrolment of patients into clinical trials is therefore strongly encouraged to further improve the outcomes for patients with advanced thyroid cancer.
KeywordsAdvanced thyroid cancer Kinase inhibitors Vandetanib Cabozantinib Sorafenib Lenvatinib
- 3.Liu Z, Hou P, Ji M, Guan H, Studeman K, Jensen K, et al. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab. 2008;93(8):3106–16.CrossRefPubMedCentralGoogle Scholar
- 13.Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, et al. BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64(19):7099–109.CrossRefPubMedCentralGoogle Scholar
- 15.Yamamoto Y, Matsui J, Matsushima T, Obaishi H, Miyazaki K, Nakamura K, et al. Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage. Vascular Cell. 2014;6:18.CrossRefPubMedCentralGoogle Scholar
- 17.Haddad RI, Schlumberger M, Wirth LJ, Sherman EJ, Shah MH, Robinson B, et al. Incidence and timing of common adverse events in Lenvatinib-treated patients from the SELECT trial and their association with survival outcomes. Endocrine. 2017.Google Scholar
- 23.Hayes DN, Lucas AS, Tanvetyanon T, Krzyzanowska MK, Chung CH, Murphy BA, et al. Phase II efficacy and pharmacogenomic study of Selumetinib (AZD6244; ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma with or without follicular elements. Clin Cancer Res. 2012;18(7):2056–65.CrossRefPubMedCentralGoogle Scholar